
NASDAQHealthcareMedical - Diagnostics & Research
最新資料
US$192.82
−US$7.835 · -3.90%
Illumina, Inc. specializes in delivering advanced genetic and genomic analysis tools, primarily through sequencing and array technologies. The company's offerings empower clients across various sectors to integrate genomic insights into both research and clinical environments, with applications spanning critical fields like life sciences, cancer diagnostics, reproductive health, agriculture, and innovative new domains. Illumina's portfolio encompasses specialized instrumentation and necessary consumables for genetic analysis, alongside comprehensive genotyping and sequencing services. They also offer instrument maintenance agreements, collaborate through development and licensing deals, and perform cancer detection tests. Its diverse clientele comprises leading genomic research facilities, universities, state-funded laboratories, medical centers, pharmaceutical and biotechnology firms, commercial molecular diagnostic providers, and businesses focused on consumer genomics. Illumina employs a two-pronged distribution strategy, selling directly to clients across North America, Europe, Latin America, and the Asia-Pacific. Additionally, it partners with life-science distributors to reach markets in Europe, the Asia-Pacific, Latin America, the Middle East, and Africa. Established in 1998, the company maintains its corporate headquarters in San Diego, California.
前收盤價
US$192.82
−US$7.835 · -3.90%
盤中時間採用ET。市場資料可能有所延遲。
Illumina, Inc. specializes in delivering advanced genetic and genomic analysis tools, primarily through sequencing and array technologies. The company's offerings empower clients across various sectors to integrate genomic insights into both research and clinical environments, with applications spanning critical fields like life sciences, cancer diagnostics, reproductive health, agriculture, and innovative new domains. Illumina's portfolio encompasses specialized instrumentation and necessary consumables for genetic analysis, alongside comprehensive genotyping and sequencing services. They also offer instrument maintenance agreements, collaborate through development and licensing deals, and perform cancer detection tests. Its diverse clientele comprises leading genomic research facilities, universities, state-funded laboratories, medical centers, pharmaceutical and biotechnology firms, commercial molecular diagnostic providers, and businesses focused on consumer genomics. Illumina employs a two-pronged distribution strategy, selling directly to clients across North America, Europe, Latin America, and the Asia-Pacific. Additionally, it partners with life-science distributors to reach markets in Europe, the Asia-Pacific, Latin America, the Middle East, and Africa. Established in 1998, the company maintains its corporate headquarters in San Diego, California.
日內區間
目前US$192.82
52週區間
目前US$192.82
盤中時間採用ET。市場資料可能有所延遲。
GoAI 評分
買進
估值
84
深度低估
情緒
54
多空交錯
風險
38
中等風險
動能
72
動能增強
完整 GoAI 研究
繼續查看更深入的依據、催化因素和風險。
Illumina, Inc. specializes in delivering advanced genetic and genomic analysis tools, primarily through sequencing and array technologies. The company's offerings empower clients across various sectors to integrate genomic insights into both research and clinical environments, with applications spanning critical fields like life sciences, cancer diagnostics, reproductive health, agriculture, and innovative new domains. Illumina's portfolio encompasses specialized instrumentation and necessary consumables for genetic analysis, alongside comprehensive genotyping and sequencing services. They also offer instrument maintenance agreements, collaborate through development and licensing deals, and perform cancer detection tests. Its diverse clientele comprises leading genomic research facilities, universities, state-funded laboratories, medical centers, pharmaceutical and biotechnology firms, commercial molecular diagnostic providers, and businesses focused on consumer genomics. Illumina employs a two-pronged distribution strategy, selling directly to clients across North America, Europe, Latin America, and the Asia-Pacific. Additionally, it partners with life-science distributors to reach markets in Europe, the Asia-Pacific, Latin America, the Middle East, and Africa. Established in 1998, the company maintains its corporate headquarters in San Diego, California.
日內區間
目前US$192.82
52週區間
目前US$192.82
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目(USD) | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 43.43億 USD | 43.72億 USD | 45.04億 USD | 45.84億 USD | 45.26億 USD |
| 銷貨成本 | 14.73億 USD | 15.11億 USD | 17.6億 USD | 16.12億 USD | 13.72億 USD |
| 毛利 | 28.7億 USD | 28.61億 USD | 27.44億 USD | 29.72億 USD | 31.54億 USD |
| 研究與開發 | 9.67億 USD | 11.69億 USD | 13.54億 USD | 13.21億 USD | 11.85億 USD |
| 銷售、一般及管理費用 | 10.86億 USD | 10.92億 USD | 16.12億 USD | 12.97億 USD | 20.92億 USD |
| 營業費用 | 20.63億 USD | 36.94億 USD | 38.13億 USD | 71.51億 USD | 32.77億 USD |
| 利息收入 | 4000萬 USD | 4600萬 USD | 5800萬 USD | 1100萬 USD | — |
| 利息支出 | 1.01億 USD | 1億 USD | 7700萬 USD | 2600萬 USD | 6100萬 USD |
| 折舊和攤銷 | 2.7億 USD | 3.54億 USD | 4.32億 USD | 3.94億 USD | 2.51億 USD |
| 營業利益 | 8.07億 USD | −8.33億 USD | −10.69億 USD | −41.79億 USD | −1.23億 USD |
| 淨利 | 8.5億 USD | −12.23億 USD | −11.61億 USD | −44.04億 USD | 7.62億 USD |
公司資料更新於 2026年11月22日。
近期已公布業績
近期已公布業績
報告持有此股票曝險的交易所交易基金。
State Street SPDR S&P 500 ETF1557.T585.43億0.05%119.93兆 JPY0.09%¥113,700-3.19%
Vanguard S&P 500 ETFVOO9.47億0.05%1兆 USD0.03%US$635.54-3.41%
Vanguard Morningstar Total Stock Market ETFVTI8.93億0.05%6893億 USD0.03%US$340.02-3.52%
Vanguard Morningstar Small-Cap ETFVB7.99億0.44%787億 USD0.03%US$270.68-2.56%
Vanguard Morningstar Small-Cap Growth ETFVBK4.47億1.04%225億 USD0.05%US$298.35-3.85%
iShares Core S&P 500 ETFIVV3.92億0.05%8034.1億 USD0.03%US$693.71-3.52%
State Street SPDR S&P 500 ETFSPY3.69億0.05%7563.79億 USD0.09%US$689.81-3.64%
iShares Biotechnology ETFIBB2.25億2.14%105.27億 USD0.44%US$199.54-2.05%
State Street SPDR S&P 500 ETF1557.T
Vanguard S&P 500 ETFVOO
Vanguard Morningstar Total Stock Market ETFVTI
Vanguard Morningstar Small-Cap ETFVB
Vanguard Morningstar Small-Cap Growth ETFVBK
iShares Core S&P 500 ETFIVV
State Street SPDR S&P 500 ETFSPY
iShares Biotechnology ETFIBBAI 生成內容及延遲市場資料僅供資訊與教育用途,不構成投資建議。